Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 4/2016

01-04-2016 | Editorial

New Targets and New Treatments: Recent Advances in the Treatment of Musculoskeletal Disease

Authors: Stuart H. Ralston, Rene Rizzoli

Published in: Calcified Tissue International | Issue 4/2016

Login to get access

Excerpt

Over the past two decades, huge strides have been made in understanding the genes and molecular pathways that contribute to the pathogenesis of bone and muscle diseases. As a result of these advances, several new molecular targets have been identified for drug design and this knowledge is now being harnessed by the pharmaceutical industry to develop new drugs for the treatment of sarcopenia and metabolic bone diseases like osteoporosis, hypophosphataemic rickets, and hypophosphatasia. The current issue of Calcified Tissue International and Musculoskeletal Research highlights some of the most notable advances that have occurred in this fast developing area over recent years. …
Metadata
Title
New Targets and New Treatments: Recent Advances in the Treatment of Musculoskeletal Disease
Authors
Stuart H. Ralston
Rene Rizzoli
Publication date
01-04-2016
Publisher
Springer US
Published in
Calcified Tissue International / Issue 4/2016
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-016-0127-5

Other articles of this Issue 4/2016

Calcified Tissue International 4/2016 Go to the issue

Review

Pharmacologic Options for the Treatment of Sarcopenia

Review

Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures

Review

Alkaline Phosphatase and Hypophosphatasia

Review

Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis

Review

Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies

Review

Sclerostin Inhibition in the Management of Osteoporosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits